Oncogenic mutations as predictive factors in colorectal cancer
作者： A Lièvre , H Blons , P Laurent-Puig
DOI: 10.1038/ONC.2010.89
关键词:
摘要: … In this study, patients EGFR FISH positive and wild type for KRAS and BRAF (16% of the entire cohort) were particularly sensitive to cetuximab, with a response rate of about 80%. …
paperity.org
nature.com
researchgate.net 参考文章(100)
Katsuhiko Nosho, Takako Kawasaki, Janina A. Longtine, Charles S. Fuchs, Mutsuko Ohnishi, Yuko Suemoto, Gregory J. Kirkner, Dimity Zepf, Liying Yan, Shuji Ogino, PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations Neoplasia. ,vol. 10, pp. 534- 541 ,(2008) , 10.1593/NEO.08336
C. Bokemeyer, I. Bondarenko, A. Makhson, J. T. Hartmann, J. Aparicio, M. Zampino, S. Donea, H. Ludwig, A. Zubel, P. Koralewski, Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study Journal of Clinical Oncology. ,vol. 25, pp. 4035- 4035 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4035
Sydney D. Finkelstein, Determination of Tumor Aggressiveness in Colorectal Cancer by K-ras-2 Analysis Archives of Surgery. ,vol. 128, pp. 526- 532 ,(1993) , 10.1001/ARCHSURG.1993.01420170056008
J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, S Ogino, S Hooshmand, E Kwak, E Freed, J A Meyerhardt, Z Saridaki, V Georgoulias, D Finkelstein, C S Fuchs, M H Kulke, R A Shivdasani, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer. ,vol. 101, pp. 465- 472 ,(2009) , 10.1038/SJ.BJC.6605164
C. Bokemeyer, I. Bondarenko, J.T. Hartmann, F. DeBraud, G. Schuch, A. Zubel, I. Celik, P. Koralewski, 6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study Ejc Supplements. ,vol. 7, pp. 346- ,(2009) , 10.1016/S1359-6349(09)71174-7
Wade S. Samowitz, Hans Albertsen, Jennifer Herrick, Theodore R. Levin, Carol Sweeney, Maureen A. Murtaugh, Roger K. Wolff, Martha L. Slattery, Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer Gastroenterology. ,vol. 129, pp. 837- 845 ,(2005) , 10.1053/J.GASTRO.2005.06.020
Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A
Katsuhiko Nosho, Natsumi Irahara, Kaori Shima, Shoko Kure, Gregory J. Kirkner, Eva S. Schernhammer, Aditi Hazra, David J. Hunter, John Quackenbush, Donna Spiegelman, Edward L. Giovannucci, Charles S. Fuchs, Shuji Ogino, Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample PLoS ONE. ,vol. 3, pp. e3698- ,(2008) , 10.1371/JOURNAL.PONE.0003698
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Eric R. Fearon, Bert Vogelstein, A genetic model for colorectal tumorigenesis Cell. ,vol. 61, pp. 759- 767 ,(1990) , 10.1016/0092-8674(90)90186-I